Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: A report on 12 Danish patients

Mads Emil Bjørn, Morten Orebo Holmström, Hans Carl Hasselbalch

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstrakt

We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 109/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.

OriginalsprogEngelsk
Sider (fra-til)125-128
Antal sider4
TidsskriftLeukemia and Lymphoma
Vol/bind57
Udgave nummer1
DOI
StatusUdgivet - 2 jan. 2016

Fingeraftryk Udforsk hvilke forskningsemner 'Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: A report on 12 Danish patients' indeholder.

Citationsformater